 The purpose of this Phase II study is to evaluate the feasibility of GSK Biologicals GSK2197870A vaccine co-administered with Wyeth-Lederles PrevenarTM when given in healthy infants as a three-dose primary vaccination course at 2, 3 and 4 months of age followed by a booster dose of GSK Biologicals MenitorixTM at 12 months of age. 